# Sun Pharma Advanced Research Company Limited (SPARC)

> SPARC closed at ₹176.46 on 30 Oct 2026, trailing P/E 3.6, market cap ₹5,726 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Sun Pharma Advanced Research Company Limited (NSE: SPARC) closed at ₹176.46 on 30 Oct 2026, +36.4% over one year, against a 52-week range of ₹108.00 – ₹289.00.

In the quarter ended 30 Jun 2026 (consolidated, filed 10 Aug 2026) it reported revenue of ₹40 cr and a net loss of ₹21 cr, a -52.0% net margin; revenue grew 314.1% year on year.

On four consecutive filed quarters its trailing P/E is 3.6.

From the balance sheet dated 31 Mar 2026: return on equity -6.2%, ROCE -3.5%, debt-to-equity 0.42, Piotroski F-score 7 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 0% of 63 sector peers; PBT margin higher than 0% of 63 sector peers; ROE higher than 2% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹176.46 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -13.5% / +26.7% / +36.4% |
| 52-week low – high | ₹108.00 – ₹289.00 |
| Market capitalisation | ₹5,726 cr |
| Trailing P/E | 3.6 |
| Price / book | 4.28 |
| EV / EBITDA | 3.9 |
| Earnings yield | 27.7% |
| TTM EPS | ₹48.82 |
| TTM net profit | ₹1,584 cr |
| Quarter revenue | ₹40 cr |
| Quarter net loss | ₹21 cr |
| Net margin | -52.0% |
| Revenue growth (YoY) | +314.1% |
| Profit growth (YoY) | +60.1% |
| Return on equity | -6.2% |
| ROCE | -3.5% |
| Debt / equity | 0.42 |
| Current ratio | 2.47 |
| Free cash flow | ₹-263 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹14.3 cr |

## Questions

### What is the P/E ratio of Sun Pharma Advanced Research Company Limited?

Sun Pharma Advanced Research Company Limited's trailing P/E is 3.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026.

### What were Sun Pharma Advanced Research Company Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Sun Pharma Advanced Research Company Limited reported revenue of ₹40 cr and a net loss of ₹21 cr (consolidated), filed with the exchange on 10 Aug 2026.

### What is Sun Pharma Advanced Research Company Limited's ROE?

Return on equity is -6.2% based on the balance sheet dated 31 Mar 2026.

### Does Sun Pharma Advanced Research Company Limited have debt?

Debt-to-equity is 0.42 on the balance sheet dated 31 Mar 2026.

### What is SPARC's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, SPARC traded between ₹108.00 and ₹289.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/SPARC

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._